1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €24.46 (+289.49%). The median is €24.46 (+289.49%).
| Buy |
5 |
| Hold |
8 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | -1.29m | 212.93% |
| Gross profit | -1.29m | 246.29% |
| Net profit | 10.49m | 262.65% |
| EBITDA | -43.36m | 342.70% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €25.02m |
Number of shares | 4.05m |
52-week high/low | €10.99 - €5.52 |
| Dividends | No |
Beta | 1.06 |
P/E ratio | 0.12 |
PEG ratio | 0.00 |
P/B ratio | -0.95 |
P/S ratio | 6.20 |
Company profile
| Name | FibroGen |
| CEO | Thane Wettig |
| Employees | 34 |
